|
1
|
Chen W, Zheng R, Zeng H and Zhang S: The
incidence and mortality of major cancers in China, 2012. Chin J
Cancer. 35:732016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis C, Ma J, Bryan L and Jemal A:
Breast cancer statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zeng H, Zheng R, Zhang S, Zou X and Chen
W: Female breast cancer statistics of 2010 in China: Estimates
based on data from 145 population-based cancer registries. J Thorac
Dis. 6:466–470. 2014.PubMed/NCBI
|
|
4
|
Zhou C, He J, Li J, Fan Jh, Zhang B, Yang
Hj, Xie Xm, Tang Zh, Li H, Li Jy, et al: A nation-wide multicenter
10-year (1999–2008) retrospective clinical study of endocrine
therapy for Chinese females with breast cancer. PLoS One.
9:e1001592014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anders CK, Johnson R, Litton J, Phillips M
and Bleyer A: Breast cancer before age 40 years. Semin Oncol.
36:237–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anders CK, Hsu DS, Broadwater G, Acharya
CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, et
al: Young age at diagnosis correlates with worse prognosis and
defines a subset of breast cancers with shared patterns of gene
expression. J Clin Oncol. 26:3324–3330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Keegan TH, DeRouen MC, Press DJ, Kurian AW
and Clarke CA: Occurrence of breast cancer subtypes in adolescent
and young adult women. Breast Cancer Res. 14:R552012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee HB and Han W: Unique features of young
age breast cancer and its management. J Breast Cancer. 17:301–307.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang K, Ren Y, Li H, Zheng K, Jiang J, Zou
T, Ma B, Li H, Liu Q, Ou J, et al: Comparison of
clinicopathological features and treatments between Young (</=40
Years) and Older (>40 Years) female breast cancer patients in
West China: A retrospective, epidemiological, multicenter, case
only study. PLoS One. 11:e01523122016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Selz J, Stevens D, Jouanneau L, Labib A
and Le Scodan R: Prognostic value of molecular subtypes, ki67
expression and impact of postmastectomy radiation therapy in breast
cancer patients with negative lymph nodes after mastectomy. Int J
Radiat Oncol Biol Phys. 84:1123–1132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Elston CW, Ellis IO and Pinder SE:
Pathological prognostic factors in breast cancer. Crit Rev Oncol
Hematol. 31:209–223. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dai D, Chen B, Tang H, Wang B, Zhao Z, Xie
X and Wei W: Nomograms for predicting the prognostic value of
pre-therapeutic CA15-3 and CEA Serum Levels in TNBC patients. PLoS
One. 11:e01619022016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Di Gioia D, Dresse M, Mayr D, Nagel D,
Heinemann V and Stieber P: Serum HER2 in combination with CA 15-3
as a parameter for prognosis in patients with early breast cancer.
Clin Chim Acta. 440:16–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ebeling FC, Schmitt UM, Untch M, Nagel D,
Fateh-Moghadam A, Stieber P and Seidel D: Tumour markers CEA and CA
15-3 as prognostic factors in breast cancer-Univariate and
multivariate analysis. Anticancer Res. 19:2545–2550.
1999.PubMed/NCBI
|
|
15
|
Lee JS, Park S, Park JM, Cho JH, Kim SI
and Park BW: Elevated levels of preoperative CA 15-3 and CEA serum
levels have independently poor prognostic significance in breast
cancer. Ann Oncol. 24:1225–1231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Molina R, Auge JM, Farrus B, Zanón G,
Pahisa J, Muñoz M, Torne A, Filella X, Escudero JM, Fernandez P and
Velasco M: Prospective Evaluation of carcinoembryonic antigen (CEA)
and carbohydrate antigen 15.3 (CA 15.3) in patients with primary
locoregional breast cancer. Clin Chem. 56:1148–1157. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Molina R, Auge JM, Escudero JM, Filella X,
Zanon G, Pahisa J, Farrus B, Muñoz M and Velasco M: Evaluation of
tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients
with locoregional breast cancer: prognostic value. Tumour Biol.
31:171–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nicolini A, Colombini C, Luciani L, Carpi
A and Giuliani L: Evaluation of serum CA15-3 determination with CEA
and TPA in the post-operative follow-up of breast cancer patients.
Br J Cancer. 64:154–158. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park BW, Oh JW, Kim JH, Park SH, Kim KS,
Kim JH and Lee KS: Preoperative CA 15-3 and CEA serum levels as
predictor for breast cancer outcomes. Ann Oncol. 19:675–681. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Samy N, Ragab HM, El Maksoud NA and
Shaalan M: Prognostic significance of serum Her2/neu, BCL2, CA15-3
and CEA in breast cancer patients: A short follow-up. Cancer
Biomark. 6:63–72. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu SG, He ZY, Zhou J, Sun JY, Li FY, Lin
Q, Guo L and Lin HX: Serum levels of CEA and CA15-3 in different
molecular subtypes and prognostic value in Chinese breast cancer.
Breast. 23:88–93. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ebeling FG, Stieber P, Untch M, Nagel D,
Konecny GE, Schmitt UM, Fateh-Moghadam A and Seidel D: Serum CEA
and CA 15-3 as prognostic factors in primary breast cancer. Br J
Cancer. 86:1217–1222. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Duffy MJ: Serum tumor markers in breast
cancer: Are they of clinical value? Clin Chem. 52:345–351. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Darlix A, Lamy PJ, Lopez-Crapez E,
Braccini AL, Firmin N, Romieu G, Thezenas S and Jacot W: Serum HER2
extra-cellular domain, S100ß and CA 15-3 levels are independent
prognostic factors in metastatic breast cancer patients. BMC
Cancer. 16:4282016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee JS, Park S, Park JM, Cho JH, Kim SI
and Park BW: Elevated levels of serum tumor markers CA 15-3 and CEA
are prognostic factors for diagnosis of metastatic breast cancers.
Breast Cancer Res Treat. 141:477–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakamura K, Okada E, Ukawa S, Hirata M,
Nagai A, Yamagata Z, Kiyohara Y, Muto K, Kamatani Y, Ninomiya T, et
al: Characteristics and prognosis of Japanese female breast cancer
patients: The BioBank Japan project. J Epidemiol. 27:S58–S64. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishimiya H, Kosaka Y, Yamashita K,
Minatani N, Kikuchi M, Ema A, Nakamura K, Waraya M, Sengoku N,
Tanino H, et al: Prognostic significance of Ki-67 in
chemotherapy-naive breast cancer patients with 10-year follow-up.
Anticancer Res. 34:259–268. 2014.PubMed/NCBI
|
|
28
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: American Joint Committee on Cancer (AJCC)
Cancer Staging Manual. 7th edition. Springer-Verlag; New York:
2010
|
|
29
|
Howland NK, Driver TD, Sedrak MP, Wen X,
Dong W, Hatch S, Eltorky MA and Chao C: Lymph node involvement in
immunohistochemistry-based molecular classifications of breast
cancer. J Surg Res. 185:697–703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goud KI, Dayakar S, Vijayalaxmi K, Babu SJ
and Reddy PV: Evaluation of HER-2/neu status in breast cancer
specimens using immunohistochemistry (IHC) and fluorescence in-situ
hybridization (FISH) assay. Indian J Med Res. 135:312–317.
2012.PubMed/NCBI
|
|
31
|
Zhou P and Recht A: Young age and outcome
for women with early-stage invasive breast carcinoma. Cancer.
101:1264–1274. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zabicki K, Colbert JA, Dominguez FJ, Gadd
MA, Hughes KS, Jones JL, Specht MC, Michaelson JS and Smith BL:
Breast cancer diagnosis in women < or=40 versus 50 to 60 years:
Increasing size and stage disparity compared with older women over
time. Ann Surg Oncol. 13:1072–1077. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Freedman RA and Partridge AH: Management
of breast cancer in very young women. Breast. 22 Suppl 2:S176–S179.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chung M, Chang HR, Bland KI and Wanebo HJ:
Younger women with breast carcinoma have a poorer prognosis than
older women. Cancer. 77:97–103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wen J, Yang Y, Ye F, Huang X, Li S, Wang Q
and Xie X: The preoperative plasma fibrinogen level is an
independent prognostic factor for overall survival of breast cancer
patients who underwent surgical treatment. Breast. 24:745–750.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sidoni A, Cavaliere A, Bellezza G,
Scheibel M and Bucciarelli E: Breast cancer in young women:
Clinicopathological features and biological specificity. Breast.
12:247–250. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shao Y, Sun X, He Y, Liu C and Liu H:
Elevated levels of serum tumor markers CEA and CA15-3 are
prognostic parameters for different molecular subtypes of breast
cancer. PLoS One. 10:e01338302015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Molina R, Zanon G, Filella X, Moreno F, Jo
J, Daniels M, Latre ML, Giménez N, Pahisa J, Velasco M, et al: Use
of serial carcinoembryonic antigen and CA 15.3 assays in detecting
relapses in breast cancer patients. Breast Cancer Res Treat.
36:41–48. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Robertson JF, Jaeger W, Syzmendera JJ,
Selby C, Coleman R, Howell A, Winstanley J, Jonssen PE, Bombardieri
E, Sainsbury JR, et al: The objective measurement of remission and
progression in metastatic breast cancer by use of serum tumour
markers. European Group for Serum Tumour Markers in Breast Cancer.
Eur J Cancer. 35:47–53. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sölétormos G, Nielsen D, Schiøler V,
Mouridsen H and Dombernowsky P: Monitoring different stages of
breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J
Cancer. 40:481–486. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tomlinson IP, Whyman A, Barrett JA and
Kremer JK: Tumour marker CA15-3: Possible uses in the routine
management of breast cancer. Eur J Cancer. 31A:1–902. 1995.
|
|
42
|
Nieder C, Dalhaug A, Haukland E, Mannsåker
B and Pawinski A: Tumor marker analyses in patients with brain
metastases: Patterns of practice and implications for survival
prediction research. Tumour Biol. 36:6471–6476. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
James JJ, Evans AJ, Pinder SE, Gutteridge
E, Cheung KL, Chan S and Robertson JF: Bone metastases from breast
carcinoma: Histopathological-radiological correlations and
prognostic features. Br J Cancer. 89:660–665. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao X, Xu X, Zhang Q, Jia Z, Sun S, Zhang
J, Wang B, Wang Z and Hu X: Prognostic and predictive value of
clinical and biochemical factors in breast cancer patients with
bone metastases receiving ‘metronomic’ zoledronic acid. Bmc Cancer.
11:4032011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Harris L, Fritsche H, Mennel R, Norton L,
Ravdin P, Taube S, Somerfield MR, Hayes DF and Bast RC Jr; American
Society of Clinical Oncology, : American Society of clinical
oncology 2007 update of recommendations for the use of tumor
markers in breast cancer. J Clin Oncol. 25:5287–5312. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bast RC Jr, Ravdin P, Hayes DF, Bates S,
Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG and
Somerfield MR; American Society of Clinical Oncology Tumor Markers
Expert Panel, : 2000 update of recommendations for the use of tumor
markers in breast and colorectal cancer: Clinical practice
guidelines of the American Society of Clinical Oncology. J Clin
Oncol. 19:1865–1878. 2001. View Article : Google Scholar : PubMed/NCBI
|
